Telehealth and Memory Study

Breast cancer survivors sometimes notice problems with cognitive function—including memory, attention, and multitasking—after completing chemotherapy. UPMC Hillman Cancer Center and the Indiana University Melvin and Bren Simon Cancer Center have developed two treatments that may help breast cancer survivors improve their cognitive function, and our research team wants to learn which of these treatments is more helpful. Our study Mobile Device Treatment for Chemotherapy-Related Cognitive Change provides these treatments through a computer or smartphone, so you can participate from your home. 

Participants in this study will:

  • Take part in an initial phone screening to determine their eligibility
  • Complete questionnaires and study tests on the phone or internet before starting the treatment
  • Complete eight weeks of treatment with a psychologist using a computer or smartphone
  • Complete questionnaires and study tests over the phone or internet after completing therapy and at six months following therapy

In addition, some eligible participants can also complete an MRI scan before and after treatment. This is optional and may help our researchers understand how the treatments work in the brain so that we can improve treatments in the future. Participants who complete MRI scans will receive $50 per scan.

Eligible Patients

Our research team is seeking 200 breast cancer survivors in Indiana and Pennsylvania. Eligible patients are those who have:

  • Received chemotherapy for Stage I, II, or III breast cancer
  • Completed chemotherapy one to five years ago
  • Have concerns about attention, concentration, and memory

Participation and involvement in this study are completely voluntary and can help other women like you.

Contact us

To learn more or find out if you are eligible for this study, please contact our team.

Indiana patients, please contact:
Jessica Bailey, Study Coordinator
Phone: 317-963-7516

Pennsylvania patients, please contact:
Audrey Kreitz, Study Coordinator
Phone: 412-623-5975


This study is funded by the National Cancer Institute (grant R01 CA244673).

2656 CS/AK 11/20